Presenilin-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Presenilin-1 (PSEN1; UniProt P49768), expressed in HEK293 cells. Suited for gamma-secretase activity assays, inhibitor profiling, and antibody validation in Alzheimer's disease research.
Expression system
HEK293
Cat. #
REC-Presenilin1

In stock

SKU
REC-Presenilin1
$498.00

Target Overview

Presenilin-1 (PSEN1; UniProt P49768) is the catalytic subunit of the gamma-secretase complex, an aspartyl protease assembly that mediates intramembrane proteolysis of type I transmembrane substrates. The full-length human PSEN1 protein spans 467 amino acids and resides primarily at the endoplasmic reticulum membrane. This recombinant is produced in HEK293 cells, a mammalian expression system chosen to support native-like glycosylation and membrane topology relevant to functional studies of the gamma-secretase complex. In the cell, PSEN1 undergoes endoproteolytic cleavage into an N-terminal fragment (NTF) and a C-terminal fragment (CTF), both of which are recovered as part of the active gamma-secretase holocomplex alongside Nicastrin, APH-1, and PEN-2. This recombinant preparation is suitable for use as an antigen standard in Western blot calibration, as a positive control for immunoprecipitation, and as a reference protein for antibody validation experiments. Researchers who require a matched immunoreagent can pair this recombinant with the Triple Point Biologics Presenilin-1 antibody (SKU: RP-Presenilin1), which has been validated for Western blot against human PSEN1. Beyond antibody validation, the recombinant supports biochemical characterisation of PSEN1 interactions with complex partners and substrates including APP and Notch receptor fragments. It is also used in inhibitor and modulator binding assays, where well-characterised recombinant protein is required to assess compound selectivity and potency. The HEK293 expression system is preferred over prokaryotic hosts for membrane-associated aspartyl proteases of this class because it provides the post-translational processing context closer to the endogenous human protein, reducing the risk of misfolding artefacts that can confound functional or binding readouts.

Background

Presenilin-1 is encoded by the PSEN1 gene and functions as the catalytic aspartyl protease subunit within the gamma-secretase complex (EC 3.4.23.-). Gamma-secretase carries out regulated intramembrane proteolysis of more than 150 reported substrates, of which amyloid precursor protein (APP) and the Notch receptor family are the most extensively characterised. Cleavage of APP by gamma-secretase generates amyloid-beta (Aβ) peptides of varying lengths; the ratio of the longer Aβ42 to shorter Aβ40 species is a key variable studied in the context of amyloid plaque formation and is directly influenced by the conformation and mutational status of PSEN1. PSEN1 is one of the most intensively studied genetic loci in familial Alzheimer's disease research. Over 300 missense mutations in PSEN1 have been documented in families with early-onset autosomal dominant Alzheimer's disease, and the protein is therefore a central subject of mechanistic and pharmacological studies. Lindemann et al. (2026) describe the pharmacology of nivegacetor (RG6289), a gamma-secretase modulator in clinical development that targets the Aβ42/Aβ40 ratio, illustrating the continued importance of well-characterised PSEN1 preparations in compound profiling workflows. Separately, Dai et al. (2026) characterised a humanised knock-in mouse carrying the PSEN1 V97L mutation, a variant identified in a major Chinese early-onset Alzheimer's disease pedigree, and used it to investigate early neuroinflammatory signatures — work that underscores the value of species-matched recombinant protein for cross-validating antibody reagents across model systems. Beyond Alzheimer's disease biology, PSEN1 participates in Notch and Wnt signalling cascades. It stabilises E-cadherin/CTNNB1 complexes under basal conditions and promotes cytoplasmic CTNNB1 accumulation under apoptotic or calcium-influx conditions, providing a mechanistic link to developmental signalling studied in zebrafish and mouse models. Ricci et al. (2026) demonstrated that psen1-deficient zebrafish accumulate Aβ(1-42) and lose the PSD95 synaptic marker, a model system in which recombinant PSEN1 can serve as a biochemical reference for immunoassay calibration. This recombinant is also applicable to studies of alternative splicing of PSEN1 transcripts, a topic reviewed by Aranda-Abreu et al. (2026) as a potential modifier of neurodegeneration, and to structural and biophysical characterisation of gamma-secretase modulator binding modes. Researchers investigating white matter vulnerability in autosomal dominant Alzheimer's disease, as examined by Koops et al. (2026), require validated PSEN1 reagents for neuropathological and biomarker assay development. Triple Point Biologics has produced protease and inhibitor-related antibody and recombinant protein reagents since 1994. This preparation has validated reactivity against human PSEN1.

Applications

  • Gamma-secretase complex activity assay using fluorogenic or HTRF-based APP or Notch substrate cleavage readouts
  • Inhibitor and gamma-secretase modulator IC50 determination in binding competition or functional assays
  • Antibody validation positive control for Western blot — pairs with Triple Point Biologics RP-Presenilin1 antibody
  • Immunohistochemistry (IHC) antibody standard for PSEN1 detection in tissue sections
  • Protein–protein interaction studies with gamma-secretase complex partners (Nicastrin, APH-1, PEN-2)
  • Aβ42/Aβ40 ratio profiling assays requiring defined recombinant PSEN1 as reference material
  • Dot blot or ELISA calibration standard for quantitative PSEN1 detection in cell lysates or CSF-mimicking matrices
  • Biophysical characterisation (SPR, MST, or ITC) of small-molecule or peptide binding to the PSEN1 active site

References

  1. Dai L et al. A Humanized Knock-in Mouse Model of the PSEN1 V97L Mutation from a Major Chinese Alzheimer's Disease Pedigree Reveals Early Neuroinflammation. Neurosci Bull. 2026. doi:10.1007/s12264-026-01656-9. PMID: 42334726.
  2. Lindemann L et al. Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease. Front Pharmacol. 2026. doi:10.3389/fphar.2026.1783414. PMID: 42292846.
  3. Ricci S et al. ZL006 Treatment Reduces Inflammation, Oxidative Stress, and Brain Aβ(1-42) Accumulation and Rescues the Loss of PSD95 Synaptic Marker in Familial Alzheimer's Disease-Associated psen1-Deficient Zebrafish Model. Int J Mol Sci. 2026. doi:10.3390/ijms27114992. PMID: 42278518.
  4. Koops EA et al. Vulnerability of the locus coeruleus-entorhinal cortex white matter tract in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2026. doi:10.1002/alz.71587. PMID: 42273784.
  5. Aranda-Abreu GE et al. Alternative splicing in Alzheimer's disease: Driver, modifier, or consequence of neurodegeneration. Mech Ageing Dev. 2026. doi:10.1016/j.mad.2026.112211. PMID: 42269785.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Multi-pass transmembrane; ER + Golgi; γ-secretase complex

Frequently Asked Questions

What molecular weight does recombinant Presenilin-1 run at on SDS-PAGE and Western blot?

Full-length human PSEN1 has a predicted MW of ~52 kDa (467 aa), but endogenous PSEN1 undergoes constitutive endoproteolysis into an ~28 kDa N-terminal fragment (NTF) and ~20 kDa C-terminal fragment (CTF). Because this recombinant is produced in HEK293 cells under native-like conditions, you may observe both the uncleaved precursor near 52 kDa and the NTF/CTF cleavage products depending on reducing conditions. Under standard denaturing SDS-PAGE, expect the predominant band at ~52 kDa for the full-length form. Running a 10–12% polyacrylamide gel provides adequate resolution of all three forms.

Is recombinant Presenilin-1 the full-length protein or the cleaved NTF/CTF fragments?

The preparation contains full-length PSEN1 (residues 1–467, UniProt P49768) expressed in HEK293 cells. However, because HEK293 cells support native endoproteolytic processing, the preparation may include variable proportions of the ~28 kDa NTF and ~20 kDa CTF — the same species found in the endogenous gamma-secretase complex alongside Nicastrin, APH-1, and PEN-2. If your experiment requires strictly full-length uncleaved PSEN1, confirm the fragment profile by SDS-PAGE before use and account for both species when interpreting Western blot results.

What substrates does Presenilin-1 cleave and how do I measure gamma-secretase activity in vitro?

PSEN1 is the catalytic aspartyl protease subunit of the gamma-secretase complex, mediating intramembrane proteolysis of type I transmembrane substrates including APP (generating Aβ peptides) and Notch (releasing the NICD). For in vitro activity, fluorogenic peptide substrates derived from the APP transmembrane domain (e.g., NMA/DNPK-based quenched peptides) are widely used. Activity requires assembly of the full holocomplex; isolated recombinant PSEN1 alone has minimal catalytic activity. Use this recombinant primarily as an antigen standard, immunoprecipitation positive control, or antibody validation reference rather than a standalone enzyme for cleavage assays.

What buffer should I use when setting up assays with recombinant Presenilin-1?

This recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — a standard stabilizing buffer suitable for immunoprecipitation and Western blot calibration applications. For functional reconstitution experiments, note that gamma-secretase activity is typically assessed in detergent-solubilized membrane preparations (e.g., CHAPSO or DDM) supplemented with phosphatidylcholine/phosphatidylethanolamine lipids; the supplied buffer alone is not optimized for intramembrane proteolysis assays. Avoid diluting below the stability threshold without carrier protein (0.1% BSA is a common supplement). Do not add reducing agents at high concentrations, as these can disrupt the aspartyl protease active site.

What starting concentration of recombinant Presenilin-1 should I use for antibody validation or IP positive control?

For Western blot antigen standard use, 50–200 ng per lane provides a strong, reproducible signal with most anti-PSEN1 antibodies, including the matched TPB rabbit polyclonal (RP-Presenilin1). For immunoprecipitation positive control, a starting input of 0.5–1 µg per reaction is sufficient when using standard Protein A/G bead protocols. Titrate down from 200 ng on your first Western blot run to identify the linear detection range for your specific antibody concentration and chemiluminescence system. Because purity is >90% by SDS-PAGE and endotoxin is <0.1 EU/µg, background contributions from contaminants are minimal.

Can I use recombinant Presenilin-1 as a positive control for Western blot with the RP-Presenilin1 antibody?

Yes — this is a validated use case. The matched rabbit polyclonal antibody RP-Presenilin1 (/anti-presenilin-1-rabbit-polyclonal-antibody) was produced and validated in the same laboratory as this recombinant, ensuring antigen-antibody compatibility. Load 50–100 ng of recombinant PSEN1 per lane alongside your cell lysate samples; the antibody should detect the ~52 kDa full-length band (and potentially NTF/CTF fragments) under standard PVDF or nitrocellulose transfer conditions. This pairing eliminates ambiguity about whether a negative result in your lysate reflects poor antibody performance versus true target absence.

How much recombinant Presenilin-1 should I load for a Western blot positive control lane?

Load 50–150 ng per lane as a starting point. At 50 ng, the ~52 kDa full-length PSEN1 band is typically detectable with the matched RP-Presenilin1 rabbit polyclonal at a 1:1,000–1:2,000 dilution using standard HRP-conjugated secondary antibodies and ECL detection. If you are using a different anti-PSEN1 antibody, begin at 100 ng to account for variable sensitivity. Running a 3-point dilution series (50, 100, 200 ng) on your first blot establishes a working curve and confirms linearity within your detection system.

How should I store recombinant Presenilin-1 and what is the shelf life after aliquoting?

Store at -20°C in single-use aliquots immediately upon receipt. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) provides adequate cryoprotection at -20°C. Avoid repeated freeze-thaw cycles — each cycle can cause measurable aggregation and activity loss for membrane-associated proteins like PSEN1. Properly stored aliquots are stable for up to 12 months from the date of manufacture. Once thawed, keep on ice and use within the same working session. Do not refreeze a thawed aliquot. For long-term archival storage beyond 12 months, -80°C is recommended.

Validation imagery coming soon

Western blot validation figures for REC-Presenilin1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →